Kyowa Kirin cooperation extended
April 1, 2020 The company ExCEEd Orphan announces its consulting cooperation expansion with
AveXis receives positive CHMP opinion for Zolgensma®
AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal
Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma®
Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma®
Rare Disease Day support
ExCEEd Orphan is honoured and engaged to support Rare Disease Day campaign and
Cooperation with Kyowa Kirin
The company ExCEEd Orphan announces its consulting cooperation with Kyowa Kirin (https://www.kyowakirin.com/) in
Further Cooperation with Akcea
ExCEEd Orphan announces a further consulting cooperation with Akcea Therapeutics in the CEE
AveXis receives FDA approval for Zolgensma®
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for
Akcea and Ionis Announce Approval of WAYLIVRA®
Akcea and Ionis Announce the approval of WAYLIVRA® (volanesorsen) in the European Union.
Cooperation with AveXis
ExCEEd Orphan announces its cooperation with AveXis (https://www.avexis.com/) in relation to the Spinal